
POLICY DETERMINATION



Blue Cross
Blue Shield
Blue Care Network
of Michigan

Nonprofit corporations and independent licensees
of the Blue Cross and Blue Shield Association

Current Policy Effective Date: 8/5/26
(See policy history boxes for previous effective dates)

Title: 90616 – mFlusiva Influenza Trivalent mRNA Vaccine

Brief Description of Service:

This code represents mFlusiva (mRNA-1010), an mRNA-based trivalent, influenza vaccine administered by intramuscular injection to reduce the risk of contracting influenza. The vaccine targets three strains of the influenza virus: A/H1N1, A/H3N2 and B/Victoria. The dosage is 37.5 mcg/0.38 mL.

The manufacturer is Moderna.

The CPT code for this vaccine is effective 7/1/2026.

The U.S. Food and Drug Administration approved this vaccine on August 5, 2026 for use in individuals 50 years of age and older.

Recommendation:

The safety and effectiveness of the trivalent, mRNA-based influenza vaccine, mFlusiva, is established.

CPT/HCPCS Level II Codes *(Note: The inclusion of a code in this list is not a guarantee of coverage. Please refer to the medical policy statement to determine the status of a given procedure.)*

Established codes:

90616

Other codes (investigational, not medically necessary, etc.):

NA

References:

1. CPT® 90616, Under Vaccines, Toxoids. Codify by AAPC. <https://www.aapc.com/codes/cpt-codes/90616?srsId=AfmBOopzGPVYP7Aqiy7B870MLjiA9NMQK8DNMUQhioa4fFDhuii3CZcc> Accessed July 6, 2026.
2. American Medical Association CPT® Category I New Immunization Vaccine Codes. <https://www.ama-assn.org/system/files/vaccine-long-descriptors.pdf> Accessed July 6, 2026.
3. U.S. Food & Drug Administration. FDA Approval Letter, August 5, 2026 <https://www.fda.gov/media/194121/download?attachment> Accessed August 7, 2026.
4. U.S. Food & Drug Administration. Vaccines Licensed for Use in the United States. <https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states> Accessed August 7, 2026.

Joint Blue Cross/BCN Medical Policy History

Policy Effective Date	Blue Cross Signature Date	BCN Signature Date	Comments
8/5/26	8/18/26		Joint policy established; retired, as this vaccine is FDA-approved. (Is)

Next Review Date: NA

RETIRED